Abstract. Granulopoiesis-related genes are distinctively upregulated in peripheral leukocytes of patients with antineutrophil cytoplasmic autoantibodies (ANCA)-associated glomerulonephritis. Affymetrix microarrays identified the upregulation of nine neutrophilic primary granule genes, including myeloperoxidase (MPO) and proteinase 3 (PR3), plus five secondary granule genes. Coordinate expression of granulocyte maturation marker CD35, measured by TaqMan PCR, and positive in situ staining for PR3 transcripts in polymorphic neutrophils and monocytes indicate that these genes are expressed in "mature" cells. Increased transcripts correlated with disease activity and absolute neutrophil values but not with "left shift," drug regimen, cytokine levels, hematuria, proteinuria, ANCA titer, serum creatinine, gender, or age. Upregulation of PR3 and MPO transcripts was specifically associated with ANCA disease (n ϭ 56) as these changes were not detected in patients with ESRD (n ϭ 25) or systemic lupus erythematosus (n ϭ 17), as determined by TaqMan PCR. This is the first report of this phenomenon in nonneoplastic cells. The data raise the hypothesis that, in addition to the presence of anti-MPO or anti-PR3 autoantibodies, a second critical component in the cause of this disease is the reactivation of once-silenced genes leading to increased antigen availability.
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During the later stages of neutrophil maturation, large portions of chromatin condense, causing the morphologic appearance of the nucleus to change to a linear array of three or four lobes joined by thin DNA-containing filaments. These nuclear changes are part of a differentiation program that results in maturation-linked gene silencing (1, 2) . In particular, transcription of primary granule constituents is terminally silenced once a granulocyte matures and leaves the bone marrow (3) . For example, myeloperoxidase (MPO) and proteinase 3 (PR3) mRNA transcripts are found almost exclusively at the early promyelocyte stage. Neutrophil elastase transcripts are found in blasts and disappear as the promyelocytes further differentiate (4) .
Microarrays are now used to fingerprint biologic and pathologic processes. In general, these "gene profiling" missions are hypothesis generating rather than hypothesis driven. We are utilizing Affymetrix microarrays as a first step into investigations of whether gene expression patterns of circulating leukocytes can be used as functional fingerprints of kidney disease (5) (6) (7) . In the present study, we sought to identify gene expression profiles in peripheral blood leukocytes that correlate with disease activity of antineutrophil cytoplasmic autoantibodies (ANCA) vasculitis (8, 9) . Unexpected, the data indicated that genes that normally are silenced in mature peripheral blood leukocytes are actively transcribed in these patients. Two of the genes identified, MPO and PR3, are the primary autoantigens recognized by ANCA (10, 11) . This finding of abnormally expressed genes in ANCA patients raises the hypothesis that in this disease, a pathologic component, equally as important as the presence of anti-MPO or anti-PR3 autoantibodies, is the reactivation of once-silenced genes. This "second hit" would increase antigen availability and may be required for fulminant disease. Our current understanding of the pathogenic process of ANCA-associated disease is that the process is launched when ANCA bind to their antigens on the surface of neutrophils and monocytes, thus causing them to release azurophilic granules that contain toxic radicals, destructive enzymes, and proteases (12) (13) (14) (15) . On the basis of these observations, we surmised that the amount of antigen available for interaction with the autoantibodies will influence the amplitude of these effects, and, indeed, increased membrane expression of the antigens correlates with disease activity (16) . In line with this hypothesis, genetic factors that enhance surface expression of these proteins are thought to predispose individuals to ANCA-mediated vasculitis (16) . In addition to genetic factors, cytokines seem to influence PR3 and MPO surface expression (17, 18) .
From this information, the inference is that abundant antigen on the surface of neutrophils and monocytes makes them susceptible to attack by ANCA, and we now have compelling evidence that attack by ANCA in vivo is pathogenic. Pathogenicity was demonstrated in a recently developed animal model in which glomerulonephritis and vasculitis identical to human ANCA disease was induced by injecting anti-MPO IgG into mice (19) . At the molecular level, ANCA affect cellular signaling pathways, causing global changes in gene transcription, and this effect, at least in part, depends on antigen-ANCA interactions. Specifically, leukocytes from healthy volunteers that were exposed to ANCA IgG or ANCA-F(ab') 2 in vitro are stimulated to transcribe a distinct subset of genes (7). The experiments described herein test the hypothesis that, in patients with ANCA disease, there is association between disease activity and "reexpression" of genes coding for ANCA antigens in circulating leukocytes.
Materials and Methods
ANCA patients were identified through the Glomerular Disease Collaborative Network, listed in Table 1 . ANCA patients were categorized as microscopic polyangiitis, Wegener's granulomatosis, Churg-Strauss syndrome, or renal-limited pauciimmune necrotizing and crescentic glomerulonephritis, as defined by the Chapel Hill Consensus Conference (20) . The severity of disease activity was ranked on the basis of the Birmingham Vasculitis Activity Score (BVAS) 2002 version: remission (R; BVAS 0), activeϩ (Aϩ; BVAS 1 to 9), and activeϩϩ (Aϩϩ; BVAS 10 to 28). ANCA samples (n ϭ 68) were collected from 44 patients (17 
RNA Purification
Total leukocytes were obtained by lysis of erythrocytes in blood using NH 4 Cl lysis buffer (7) . For analysis of specific types of leukocytes, neutrophils, monocytes, and lymphocytes were separated by Accuspin System-Histopaque-1077 (Sigma, St. Louis, MO), NH 4 Cl lysis buffer, and MACS Monocyte Isolation Kit (Miltenyi Biotec, Auburn, CA). RNA was extracted using RNA STAT-60 (Tel-Test "B", Friendswood, TX) and DNase treated (7, 21) .
Microarray Data Processing
The Affymetrix U97 Microarray GeneChip was used for identification of differentially expressed genes, as described by Affymetrix (Palo Alto, CA). This procedure was performed at Gene Logic as described previously (22) . Three parameters were used for analysis, average difference intensity change, difference call, and fold change. Gene expression levels that varied Ͻ1.5-fold relative to the biologic base line or had a difference call of "no change," as determined by the GeneChip algorithms, were considered unchanged.
The "present" versus "absent" call is based on a Detection P value. The analysis indicates whether a transcript is reliably detected (present) or not detected (absent). The score is calculated for each probe pair and is compared with a predefined threshold Tau. Probe pairs with scores higher than Tau vote for the presence of the transcript. The higher the discrimination scores are above Tau, the smaller the P value and the more likely the transcript will be present.
TaqMan PCR
Quantitative PCR assays were performed on an ABI PRISM 7900 HT sequence detection system (Applied Biosystems, Foster City, CA), using the TaqMan EZ RT-PCR kit (Applied Biosystems). Primers and probes were designed using Primer Express software (Applied Biosystems). Primers and probes for cyclophilin A were purchased from Applied Biosystems. SYBR green 1 (fluorescence detector) was from Molecular Probes (Eugene, OR GATAT (bp 250 to 273). Relative level of a specific mRNA was determined by standard 2 (Ϫ⌬⌬Ct) calculations and expressed as fold change of a reference control sample. Cyclophilin A was used as RNA loading standard (7).
In Situ Hybridization
Leukocytes from buffy coats were fixed with 10% buffered formalin for 30 min and attached to ProbeOn Plus slides (Fisher, Pittsburgh, PA) by cyto-spin. In situ hybridizations were performed using the ResGen Capillary Action In situ Hybridization Kit (Invitrogen, Carlsbad, CA) with some modifications. Cells were enzymatically digested using Pepsin Solution diluted 1:40 with 10 nM HCl, hybridized with 5 g/ml biotin-PR3 probe for 2 h at 37°C, and visualized using streptavidin-conjugated horseradish peroxidase and diaminobenzidine. Nuclei were stained with 4',6'-diamidino-2-phenylinndole (Sigma). For in situ hybridization-flow cytometric assays, whole blood (2 ml) was incubated with FACS lysing solution (Becton Dickinson, San Jose, CA; 20 ml) at room temperature overnight. Hybridizations were performed with 5 g/ml probe for 3 h at 37°C, and positives were detected using ImmunoPure FITC-conjugated streptavidin (Pierce, Rockford, IL) (23) . For flow cytometric quantification, PR3 mRNA levels are expressed as percentage of fluorescence intensity above glyceraldehyde-3-phosphate dehydrogenase control. The PR3 probe (nucleotides 314 to 620, GenBank X55668) was amplified by standard reverse transcription-PCR using neutrophil total RNA, and glyceraldehyde-3-phosphate dehydrogenase probe (nucleotides 982 to 1669, GenBank BC01485) was generated from HL60 cDNA. Both were subcloned into pcDNA (Invitrogen) and amplified using either SP6 (40°C) or T7 (37°C) polymerase (New England BioLabs, Beverly, MA). Additional reagents in the polymerase reaction included RNA polymerase buffer, RNase Inhibitor (Promega, Madison, WI), ATP, GTP, CTP, and a 1:6 mixture of UTP:biotin-UTP (Amersham Biosciences). Reactions were stopped with 0.2 M EDTA (pH 8.0). Single-stranded, biotinylated RNA was ethanol-precipitated, resuspended in nuclease-free water, and heated for 10 min at 60°C.
Quantification of Serum Cytokines by ELISA
ELISA kits were purchased for detection of serum IFN-␣ (PBL Biomedical Laboratories, Piscataway, NJ), granulocytecolony stimulating factor (G-CSF; Quantikine HS, R&D Systems, Minneapolis, MN), and TNF-␣ (Pierce Endogen, Rockford, IL). Cytokine concentrations were calculated according to kit instructions, and results are presented in pg/ml.
In Vitro Studies
Antibody purification and leukocyte preparation was as described previously (7) . Leukocytes from healthy volunteers were primed with 2 ng/ml recombinant TNF-␣ (R&D Systems) for 10 min. Primed leukocytes were treated with PR3-ANCA IgG, MPO-ANCA IgG, or normal IgG (200 g/ml); TNF-␣ (2 to 10 ng/ml); fMLP (10 Ϫ5 to 10 Ϫ7 M); PMA (1 to 100 nM); and LPS (0.1 to 10 g/ml) in HBSS with calcium and magnesium. Leukocytes from eight donors were analyzed in duplicate in eight independent experiments.
Statistical Analyses
Spearman rank analysis was used to calculate correlation coefficients between continuous measures. Comparisons between two groups were made using Wilcoxon rank sum tests. Differences between multiple groups were tested using the nonparametric Kruskal-Wallis test and ANOVA on ranked values. When there was an overall difference in these tests (P Ͻ 0.05), the Duncan multiple range test was then used to evaluate differences between specific group means while controlling the error rate from multiple comparisons.
Results

Peripheral Leukocytes of Patients with ANCA Disease Have Increased RNA Transcripts that Code for Granule Proteins
Affymetrix microarrays were used to evaluate the transcript levels of 33,000 genes in leukocytes from patients with ANCA disease (n ϭ 25), SLE (n ϭ 18), and RA (n ϭ 12) and from healthy volunteers (n ϭ 6). Microarray intensity values of patients' samples were compared with the intensity values of the normal controls. Analysis identified 1836 genes differentially regulated in ANCA patients (Նtwofold, P Ͻ 0.05, 685 up and 1151 down; Նthreefold, 188 up and 233 down). It is interesting that the upregulated genes were biased toward granulocyte-specific genes, and a large portion of the downregulated genes were T cell specific (data not shown). The most striking difference was the identification of 14 neutrophilgranule gene transcripts, including both primary and secondary granule proteins, significantly overrepresented in ANCA patients as compared with healthy donors (Table 2) . PR3, MPO, cathepsin G, and azurocidin were increased 4.7-to 11.2-fold in ANCA patients, compared with healthy control subjects ( Table  2) . SLE patients showed no increase in PR3 transcripts, and although there were slight increases in MPO, cathepsin G, and azurocidin. RA patient values were similar to normals.
Eight of the granule gene transcripts were sufficiently low in normal control subjects that the amount fell below a preset intensity threshold and were qualified as absent (see Materials and Methods). Of the remaining six genes, most of which were secondary granule genes, the transcript levels in normal controls were classified as present, although these six were overexpressed in ANCA patients. These data confirm previous reports that these neutrophil granule genes are not normally expressed in mature circulating PMN (3, 4, 24) .
PR3 and MPO transcript levels were assessed by TaqMan PCR in an additional group of patients with ANCA disease (n ϭ 56; active disease, n ϭ 44; remission, n ϭ 12; sample overlap with microarray study, n ϭ 13) and compared with values of healthy volunteers (n ϭ 24). PR3 (21.5 Ϯ 32.7-fold versus healthy controls 0.6 Ϯ 0.6-fold; P Ͻ 0.05) and MPO (14.8 Ϯ 21.8-fold versus healthy controls 0.9 Ϯ 0.8-fold; P Ͻ 0.05) transcripts were markedly increased in patients with ANCA disease. Spearman rank analysis indicated a tight correlation between the data derived from Affymetrix arrays versus TaqMan PCR (R 2 ϭ 0.94, P Ͻ 0.0001 for PR3; and an R 2 ϭ 0.88, P Ͻ 0.0001 for MPO; Figure 1A ). Patients with high PR3 also had high MPO levels, as indicated by Spearman rank analysis of TaqMan PCR values (R 2 ϭ 0.78, P Ͻ 0.0001; Figure 1B ). Similarly, a plot of ranked Affymetrix array values of these two genes gave an R 2 ϭ 0.78 and P Ͻ 0.0001. The data indicate a statistically significant correlation between expression of PR3 and MPO.
Spearman rank analysis of Affymetrix microarray values indicated that PR3 and MPO expression coincides with expression of the other granule proteins identified (Table 3 ). These data suggest that the mechanism responsible for upregulation of PR3 and MPO likely affects the regulation of this panel of genes.
Morphologically Mature, Circulating Neutrophils and Monocytes of ANCA Patients Express PR3 and MPO mRNA, but Lymphocytes Do Not
In situ hybridization was used to determine the leukocyte subtype(s) responsible for PR3 mRNA increases. The ma- jority of neutrophils (including segmented and band neutrophils) and monocytes were positive for PR3 message in patients with severely active ANCA, whereas the lymphocytes were negative (Figure 2 , A, D through G, representative of data from three patients). Controls included hybridization of leukocytes of ANCA patients' leukocytes with a PR3 sense probe ( Figure 2B ) and hybridization of leukocytes from a healthy donor with a PR3 antisense probe ( Figure 2C) . We found that patients with moderately active ANCA had fewer PR3-positive cells (~33% of neutrophils and 50% of monocytes), compared with the patient with severely active ANCA. Reproducibly, PR3-positive neutrophils and monocytes from patients with active ANCA disease were detected by flow cytometric analysis of in situ labeled cells ( Figure 2H ). Moreover, TaqMan PCR analysis of RNA from isolated leukocyte subtypes verified the upregulation of PR3 mRNA in neutrophils (PR3, 43.0 Ϯ 19.76-fold) and monocytes (PR3, 45.0-fold) but not in lymphocytes (PR3, 0.5 Ϯ 0.39-fold; Figure 2I ). MPO transcripts were detected in neutrophils and monocytes but not in lymphocytes (data not shown).
Increases of PR3 and MPO Expression Are Not Due to a "Left Shift"
The absolute neutrophil count in ANCA patients as a group was found to be elevated (9.1 ϫ 10 6 /ml versus normal range of 2.0 to 7.5 ϫ 10 6 /ml). Increases in peripheral blood neutrophils can occur normally during acute inflammation as a result of mobilization of postmitotic pools and increased production through granulopoiesis. This results in an increased number of less mature neutrophils in the circulation, termed "left shift." The question arose whether the changes in PR3 and MPO expression in ANCA patients could be related to a left shift-like phenomenon. If this were the case, then individuals with a clinical diagnosis of a left shift should have elevated PR3 and MPO transcripts. We tested a group of patients with sepsis or infection and a clinically diagnosed left shift (n ϭ 14; mean absolute neutrophil, 11.9 ϫ 10 9 /L) using TaqMan PCR. Results indicated that a left shift did not generally cause an increase in PR3 and MPO transcripts ( Figure 3A) . There was no statistical difference between the values in normal individuals and those with a left shift.
We questioned whether the increase in PR3 and MPO transcripts in ANCA patients was due to an increase in immature cells in the circulation. Examination of markers CD68, which is normally expressed in conjunction with PR3 and MPO in bone marrow cells, and CD35, a marker of mature neutrophils (3), by TaqMan PCR revealed no significant increase in CD68 in ANCA patients or in individuals with a left shift compared with normals ( Figure 3B ). CD35 was increased in both ANCA patients and in patients with a left shift, which correlates with a higher absolute neutrophil count. Spearman rank analyses indicated a slight correlation between CD35 and both PR3 (R 2 ϭ 0.3, P Ͻ 0.05) and MPO (R 2 ϭ 0.3, P Ͻ 0.05) but not with CD68 (R 2 ϭ 0.02, P Ͼ 0.05). However, in left shift patients, there was no correlation between CD35 and PR3 levels (R 2 ϭ 0.03, P Ͼ 0.05).
In Vitro Studies to Elucidate Factors Involved in the Changes of PR3 and MPO Transcription in ANCA Patients
Because leukocytes of ANCA patients are exposed to reactive autoantibodies in the circulation, we asked whether the antibodies themselves are instrumental in inducing PR3 and MPO transcription. Leukocytes from healthy volunteers were exposed in vitro to PR3-ANCA IgG, MPO-ANCA IgG, or normal IgG and analyzed by TaqMan PCR. Neither PR3 nor MPO levels were increased, whereas IL-8 increased dramatically (40-fold; Figure 4A ). TNF-␣ plus and minus fMLP, PMA, or LPS would not induce PR3 and MPO ( Figure 4B ). Our conclusion is that the presence of the autoantibodies or other neutrophil-activating agents in patients does not explain the transcriptional changes in their leukocytes.
Increased Serum Cytokine Levels Do Not Correlate with PR3/MPO Transcript Increases
We questioned whether ANCA patients with high PR3 and MPO also had increased serum levels of TNF-␣, G-CSF, or IFN-␣. With limitations on the availability of serum samples that were time matched with the RNA samples, of 22 ANCA patients, six had slightly elevated levels of TNF-␣ (15 to 28 pg/ml versus normal, 1 to 12 pg/ml), eight had increased G-CSF (25 to 118 pg/ml versus normal, 12 to 23 pg/ml), and three had increased IFN-␣ (11 to 23 pg/ml versus normal, 1 to 5 pg/ml). Spearman rank analysis indicated no correlation of PR3 increases with TNF-␣ (R 2 ϭ 0.20), G-CSF (R 2 ϭ 0.01), or IFN-␣ (R 2 ϭ 0.01; Figure 5A ). We analyzed a group of septic patients with a left shift and/or patients with a high neutrophil count (Table 4) . Increased cytokine levels in these individuals did not correlate with increased PR3 transcripts.
Statistical Correlations of Patient Clinical Data with Transcription of PR3 and MPO
The general drug regimen for patients with ANCA disease includes corticosteroids, cyclophosphamide, and mycophenolate mofetil (MMF) either alone or in combination. We determined whether there was a correlation between a particular drug therapy versus PR3 and MPO expression. Patients on corticosteroids, including those with and without additional medications (21 active disease, six remission), had a mean fold increase in PR3 transcripts of 16.80 Ϯ 23.51. The remaining patients who were not on corticosteroids (23 active disease, six remission) had a mean fold increase in PR3 of 25.79 Ϯ 39.26. There was no statistical difference between the two groups (P ϭ 0.30). PR3 levels in the nine patients on cyclophosphamide therapy averaged 14.40 Ϯ 23.58-fold, which was not statistically different from levels in patients who were not on cyclophosphamide (22.81 Ϯ 34.16-fold; P ϭ 0.38). However, the 13 patients who were on MMF therapy had reduced levels of PR3 of 5.91 Ϯ 6.06-fold (P ϭ 0.0009), a significant reduction compared with those who were not on MMF with a mean of 26.16 Ϯ 35.90. In all cases, comparisons of drug therapy and MPO expression mimicked those of PR3 ( Figure 5B ).
For further proof that corticosteroids do not cause circulating leukocytes to transcribe PR3/MPO, we analyzed the SLE patient group, of which corticosteroids is a primary course of therapy. PR3 levels in the nine of 17 patients who were on corticosteroids averaged 0.89 Ϯ 1.45-fold, compared with the eight who were not with an average of 1.14 Ϯ 1.31-fold. These two groups were not statistically different (P ϭ 0.72). Likewise, MPO levels were not statistically different between the treated and untreated groups (P ϭ 0.74). Note, of the patient samples used for the microarray studies, the 12 RA patients included five on corticosteroids and three on methotrexate, and the 18 SLE patients included 10 on corticosteroids, three on cyclophosphamide, and four on MMF. The data indicate that corticosteroids and cyclophosphamide are not responsible for increased transcripts of PR3 and MPO, but, intriguing, MMF therapy may be associated with decreases in PR3 transcription.
ANCA titers did not correlate with either PR3 or MPO transcript increases (PR3-ANCA, P ϭ 0.13; MPO-ANCA, P ϭ 0.30), and there was an equal probability (P Ͼ 0.05) for increases in PR3 and/or MPO RNA to occur in PR3-ANCA patients versus MPO-ANCA patients. Increased PR3 and MPO levels did not correlate with patient gender, age (16 to 49 versus 50 to 82), C reactive protein (Յ2 versus Ͼ2 mg/dl), ESR (Յ20 versus Ͼ20 mm/h), hematuria (0 versus Ն1ϩ), or proteinuria (0 versus Ն1ϩ). Neither did serum creatinine correlate (mean, 2.6 Ϯ 2.7 mg/dl), regardless of whether the patient had a high or normal level. The mean serum creatinine concentration in the PR3/MPO-expressing ANCA patient group (2.6 Ϯ 2.7 mg/dl) was significantly lower than the ESRD group (6.6 Ϯ 3.0 mg/dl; P Ͻ 0.05) and significantly higher than the SLE group (1.1 Ϯ 0.6 mg/dl; P Ͻ 0.05), confirming the lack of correlation between PR3/MPO transcription and serum creatinine levels.
Correlation of Increased PR3 and MPO mRNA Levels with Disease Activity
On the basis of disease activity (BVAS values), patients were categorized into three groups: activeϩϩ; activeϩ; and remission. Transcript levels of PR3 and MPO, based on TaqMan PCR values, were highest in the activeϩϩ group (PR3, 32.7 Ϯ 37.5-fold; MPO, 25.1 Ϯ 28.1-fold), decreasing slightly in the activeϩ group (PR3, 19.6 Ϯ 32.7-fold; MPO, 11.2 Ϯ 15.7-fold) and only slightly elevated above normal values in the remission group (PR3, 4.2 Ϯ 4.1-fold; MPO, 2.6 Ϯ 2.2-fold; Figure 6 ). All three patient groups (B) Statistical analysis to determine any association of PR3/MPO increases with a particular drug therapy. Corticosteroids (CS) and cyclophosphamide (CP) had no effect on PR3/MPO levels, whereas mycophenolate mofetil (MMF) significantly reduced PR3/MPO levels.
were statistically different compared with normals (P Ͻ 0.05), and the remission group was statistically different from the activeϩϩ group (P Ͻ 0.05). This observation is consistent with the in situ hybridization data showing a direct correlation between number of positive cells and disease activity.
Transcription of PR3 and MPO Is Specifically Associated with ANCA Vasculitis
To delineate further a disease-specific association, we used TaqMan PCR to assess quantitatively the levels of PR3 
Discussion
We hypothesized~5 yr ago that we could monitor kidneyrelated diseases by analyzing gene expression profiles of circulating leukocytes (6, 7) . During these research efforts, we discovered that peripheral blood leukocytes from patients with ANCA disease are expressing genes that normally are expressed only in immature bone marrow cells. This finding, which we believe has broad implications for understanding ANCA disease, set off a series of experiments to elucidate the basis of this observation. We found that peripheral, mature neutrophils and monocytes of these patients had increased transcript levels of a group of genes that normally are expressed only in bone marrow precursor cells. This anomaly seems to be ANCA disease specific, as upregulation of these genes was not observed in patients with ESRD, SLE, or RA or in healthy volunteers. Further supporting the uniqueness of this observation is a published expression profile of genes actively transcribed in human peripheral granulocytes in which, of 748 species, defensin was the only granule protein gene detected (25) . In a second study, investigators analyzed global gene expression in neutrophils that were exposed to nonpathogenic Escherichia coli K12 and found that cathepsin D was the only upregulated granule gene (26) .
These findings raise a crucial question of whether increased transcription of PR3/MPO in these patients causes increased PR3/MPO protein on the cell surface, placing them at risk for the development of ANCA-mediated disease. Indeed, in our studies, upregulation of PR3/MPO message was correlative with disease activity, and others have shown increased membrane expression of the protein in active disease (16) . A recent report introduced the concept that subsets of neutrophils express PR3 molecules on their surface and that the proportion of neutrophils that present PR3 is genetically controlled (27) . The authors found that the phenotype of increased PR3 surface expression was significantly increased in patients with ANCAassociated vasculitis, and our observations of increased PR3 message provide a mechanistic explanation for their observations. Moreover, patients with small-vessel vasculitis had increased levels of circulating PR3 protein in their plasma, and the type of ANCA (PR3-ANCA or MPO-ANCA) was of no significance (21) . Reversal of transcriptional irregularities associated with ANCA disease activity may prove to be an important target for intervention.
The only setting, other than in neoplastic cells, that expression of any of these developmentally silenced genes has been detected outside of the bone marrow is in cystic fibrosis patients who had increased PR3 message at the time of cystic fibrosis pulmonary exacerbation, although MPO was not upregulated (28) . There is no evidence of de novo biosynthesis of PR3 in neutrophils during infection, although there is some evidence that the inflammatory environment stimulates PR3 transcription in monocytes (29) . Three biologic agents that are reported to activate PR3 transcription in vitro are G-CSF, IFN-␣, and TNF-␣ (30 -32). However, the serum levels of these cytokines in ANCA patients tested here did not correlate with PR3 transcription.
The ANCA patients who were on an MMF drug regimen had significantly reduced levels of PR3 and MPO transcripts. This suggests that a PCR-based assay for PR3/MPO leukocyte levels could serve both as a method to monitor drug efficacy and as a marker of disease. Identification of specific drug targets and their association with PR3 expression is confounded by complexities of the drugs. They each have different mechanisms of action, and it is likely that high-dose effects may be mechanistically different from low-dose effects. Another complexity is that many patients are on a combination of drugs. The combination of drugs does not simply elicit the additive effects of a single agent.
An important question that arises is the cause of the abnormal gene expression. Evidently, leukocytes in these patients have additional phenotypic anomalies. Indications from in vitro studies are that circulating neutrophils of ANCA patients exist in an activated state, expressing activation markers CD66b, CD64, and CD63 (33) . These findings are predicted to be analogous to conditions in vivo. In support, we found that both leukocytes treated in vitro with ANCA and leukocytes from patients with ANCA disease express increased levels of DIF-2, which correlated strongly with disease activity and ANCA titer (7). One speculation is that an inflammatory/ infectious response is involved.
Many questions remain unanswered regarding the transcriptional regulation of granulocyte and monocyte genes in these patients. How irreversible are commitment decisions? We discovered that a battery of normally silenced genes are actively transcribed in peripheral blood leukocytes of patients with ANCA disease, and even more relevant to this particular disease, two of these genes are PR3 and MPO, which are ANCA antigens. Are there additional important transcriptional regulators of myeloid genes remaining to be uncovered via detailed investigation of promoters and distal enhancers? With respect to key transcription factors, further clarification of the regulatory network is needed. The answers to these questions may prove informative in revealing pathogenic mechanisms of ANCA.
